Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine

被引：4

作者：

Kuriyama, Kodai ^{[1
]}

Kitamura, Yoshimi ^{[2
,3
]}

Tsuji, Taisuke ^{[4
]}

Nishikawa, Rina ^{[1
]}

Nagata, Hiroaki ^{[1
]}

Ohshiro, Muneo ^{[1
]}

Sugitani, Mio ^{[1
]}

Hirakawa, Yoshiko ^{[1
]}

Matsumoto, Yosuke ^{[1
]}

Iwai, Toshiki ^{[1
]}

Uchiyama, Hitoji ^{[1
]}

机构：

[1] Japanese Red Cross Kyoto Daiichi Hosp, Dept Hematol, Kyoto, Japan

[2] Japanese Red Cross Kyoto Daiichi Hosp, Dept Dermatol, Kyoto, Japan

[3] Kyoto City Hosp, Dept Dermatol, Kyoto, Japan

[4] Japanese Red Cross Kyoto Daiichi Hosp, Dept Resp Med, Kyoto, Japan

来源：

CURRENT PROBLEMS IN CANCER | 2022年 / 46卷 / 02期

关键词：

Obinutuzumab; Bendamustine; Follicular lymphoma; Paraneoplastic pemphigus; Bronchiolitis obliterans; MANTLE-CELL LYMPHOMAS; OPEN-LABEL; 1ST-LINE TREATMENT; PLUS RITUXIMAB; MULTICENTER; PREDNISONE; PHASE-3; CHOP; CYCLOPHOSPHAMIDE; CHEMOTHERAPY;

D O I：

10.1016/j.currproblcancer.2021.100813

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We herein report the rare case of a 72-year-old female who presented with paraneoplastic pemphigus (PNP) and bronchiolitis obliterans (BO) associated with follicular lymphoma (FL), who was successfully treated with obinutuzumab (GA101; G) and bendamustine (B). The patient had severe erosive stomatitis and bilateral conjunctival hyperemia that persisted for more than 6 months. A huge mass was found in the abdominal cavity, and a biopsy revealed grade 1 FL (stage IV). Based on a lip biopsy result, the pa-tient was diagnosed with PNP associated FL. The patient received bendamustine and obinutuzumab (BG) chemotherapy and FL and PNP responded very well, but BO was additionally associated during the course of BG. BO progressed without exacerbation as BG therapy progressed to a 2 year maintenance therapy with G, and combination of azithromycin, inhaled bronchodilator therapy, and corticosteroid. She was followed up at the outpatient department with no pulmonary function decline or FL and PNP recurrence. Our case suggests that BG could be a promising treatment option for PNP and BO.(c) 2021 Elsevier Inc. All rights reserved.

引用

页数：6

共 25 条

[21] Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial [J].

Rummel, Mathias J. ;

Niederle, Norbert ;

Maschmeyer, Georg ;

Banat, G. Andre ;

von Gruenhagen, Ulrich ;

Losem, Christoph ;

Kofahl-Krause, Dorothea ;

Heil, Gerhard ;

Welslau, Manfred ;

Balser, Christina ;

Kaiser, Ulrich ;

Weidmann, Eckhart ;

Duerk, Heinz ;

Ballo, Harald ;

Stauch, Martina ;

Roller, Fritz ;

Barth, Juergen ;

Hoelzer, Dieter ;

Hinke, Axel ;

Brugger, Wolfram .

LANCET, 2013, 381 (9873) :1203-1210

[22] Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial [J].

Salles, Gilles ;

Seymour, John Francis ;

Offner, Fritz ;

Lopez-Guillermo, Armando ;

Belada, David ;

Xerri, Luc ;

Feugier, Pierre ;

Bouabdallah, Reda ;

Catalano, John Vincent ;

Brice, Pauline ;

Caballero, Dolores ;

Haioun, Corinne ;

Pedersen, Lars Moller ;

Delmer, Alain ;

Simpson, David ;

Leppa, Sirpa ;

Soubeyran, Pierre ;

Hagenbeek, Anton ;

Casasnovas, Olivier ;

Intragumtornchai, Tanin ;

Ferme, Christophe ;

da Silva, Maria Gomes ;

Sebban, Catherine ;

Lister, Andrew ;

Estell, Jane A. ;

Milone, Gustavo ;

Sonet, Anne ;

Mendila, Myriam ;

Coiffier, Bertrand ;

Tilly, Herve .

LANCET, 2011, 377 (9759) :42-51

[23] A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies [J].

Tobinai, Kensei ;

Klein, Christian ;

Oya, Naoko ;

Fingerle-Rowson, Gunter .

ADVANCES IN THERAPY, 2017, 34 (02) :324-356

[24] Paraneoplastic pemphigus: a short review [J].

Wieczorek, Marta ;

Czernik, Annette .

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2016, 9 :291-295

[25]

Wu SS, 2020, INT J CLIN EXP PATHO, V13, P1915

← 1 2 3 →